Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The cytokines cardiotrophin-like cytokine/cytokine-like factor-1 (CLC/CLF) and ciliary neurotrophic factor (CNTF) differ in their receptor specificities.
Functional role of TRP channels in modulating ER stress and Autophagy.
Multiple sclerosis disease-modifying therapy prescribing patterns in ontario.
The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis.
Epistasis and immunity: the role of genetic interactions in autoimmune diseases.
Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis (PROMESS)
Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.
Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis.
Multiple sclerosis remission following antiretroviral therapy in an HIV-infected man.
Prospective Examination of Anxiety and Depression Before and During Confirmed and Pseudoexacerbations in Patients With Multiple Sclerosis.
Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.
Sex ratio of multiple sclerosis in Canada: a longitudinal study.
Myelination of the nervous system: mechanisms and functions.
Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study.
Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis.
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
Partnering to increase access to community exercise programs for people with stroke, acquired brain injury, and multiple sclerosis.
Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b.
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration.
Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells.
Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study.
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS] (RECYCLINE)
Eosinophilic Fasciitis Occurring under Treatment with Natalizumab for Multiple Sclerosis.

Pages